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Comments people with diabetes receiving palliative care
made during individual interviews conducted as part of the
consumer consultation process as the Guidelines were
developed.
Yeah, the patients shouldn’t have to worry about it…
that’s the only thing I would say that it’s [diabetes] not given
as high a priority probably as it should be.
You don’t want to go on with endless care… you’ve got to
draw a line somewhere but I think I would like to feel
comfortable but not be overactive with treatment and I feel
that’s not done.
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FOREWORD
The prevalence of diabetes is increasing and people with diabetes are living longer, however, they frequently have significant
complications of diabetes and other comorbidities that affect their quality of life and require palliation.  The focus of diabetes
management in palliative care settings may need to change from tight metabolic control to prevent medium to long term
diabetic end organ disease to managing symptoms, maximising quality of life and achieving a peaceful death.
Often health professionals believe monitoring blood glucose levels and continuing diabetes medicines, especially insulin,
represents intrusive disease-modifying treatment. However, hypo- and hyperglycaemia produce unpleasant symptoms that
affect comfort and quality of life and can exacerbate pain.  The ‘textbook’ symptomatic presentations of these metabolic
derangements may not be present or be hard to distinguish from symptoms due to another life threatening illness unless
blood glucose monitoring occurs.  Likewise, medicines, including insulin, may be required to control hyperglycaemia.
Hyperglycaemia occurs as a result of medicines such as corticosteroids, commonly used in palliative care contexts, and
physical stressors such as dehydration and pain as well as psychological stress and depression, and can lead to ketoacidosis
or hyperosmolar states and unnecessary hospital admissions.
There is very little ‘gold standard’ evidence for managing diabetes at the end of life mainly because dying people are a
very vulnerable group and recruitment is difficult.  Thus, it was difficult to identify any Level 1 evidence to support the care
suggested in the Guidelines.  However, an expert interdisciplinary advisory group consisting of palliative care and diabetes
clinicians reviewed the existing literature and provided expert comment during the development of the guidelines.  In
addition, people with diabetes at the end stages of life and their family members were interviewed.  The majority indicated
they preferred an individualised approach including monitoring their blood glucose and continuing their diabetes medicines
including insulin to prevent excursions in blood glucose until they were actively dying and unconscious.
We are very grateful to these people for willingly and openly discussing such an emotive topic, at such a difficult time for
the patients and their carers, and the valuable insights all the contributors provided. We commend the guidelines to you
in their name and honouring the memories of those who are no longer with us.
        
Trisha Dunning         Peter Martin
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Guidelines for managing diabetes at the end of life
The guidelines use the Palliative Care Outcomes Collaboration (PCOC) palliative care phases of stable,
unstable, deteriorating and terminal.
STABLE PHASE: The person’s symptoms are adequately controlled on their established management plan
but interventions to maintain symptom control and quality of life have been planned.
UNSTABLE PHASE: The person develops a new unexpected problem or a rapid increase in the severity
of existing problems.
DETERIORATING PHASE: The person’s existing symptoms gradually worsen or they develop new but
unexpected problems.
TERMINAL PHASE: Death is likely in a matter of days and no acute intervention is planned or required.
HOW TO USE THESE GUIDELINES
Part 1 is a SCREENING PROCESS for all people when they are first referred to palliative care
regardless of PCOC phase.
Use Part 1, Section A if they are known to have diabetes.
Use Part 1, Section B if their diabetes status is unknown.
Part 2 is the recommended DIABETES MANAGEMENT at each PCOC phase.
Determine the PCOC phase of a palliative care patient and use the appropriate section.
Use Part 2, Section A for stable phase.
Use Part 2, Section B for unstable phase.
Use Part 2, Section C for deteriorating phase.
Use Part 2, Section  D for terminal phase.
Part 3 is recommendations for MANAGING STEROIDS and other diabetogenic medicines (as listed on
Page 2 of the accompanying document) in palliative care patients. People requiring palliative care who
are prescribed steroid medicines and some other medicines may develop diabetes.
Use Part 3, Section A for type 1 diabetes.
Use Part 3, Section B for type 2 or previously undiagnosed diabetes.
INDEX
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RT
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RT
  3
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Guidelines for managing diabetes at the end of life Part 1, Section A
*Palliative Care Outcomes Collaboration (PCOC)
Screening process for all people when they are first
refered to palliative care, regardless of PCOC* phase
KNOWN TO HAVE
DIABETES
If the person is using diabetogenic medicines:
• Review need to continue diabetogenic medicines
• Adjust/commence oral hypoglycaemic agents
(OHA) or insulin to control hyperglycaemic
symptoms and promote comfort
• Monitor according to Managing Steroid Guidelines
(refer to Part 3, Section A/B) but individualise
according to Advanced Care Directive and
PCOC phase
• Provide education about steroids and diabetes
• Consider adrenal suppression and hypercalcaemia
as complicating factors if steroids are needed in
the long term
• Assess enteral feeds – may lack carbohydrate and
therefore contribute to lethargy OR may be high
calorie and contribute to hyperglycaemia
• Readjust OHA/insulin doses if steroids are
ceased and when weaning the dose to avoid
hypoglycaemia
If the person is NOT using diabetogenic medicines:
• Provide usual diabetes management and education
according to relevant diet and activity guidelines
• Adjust OHA/insulin as appropriate
• Consider referring to:
- Treating Specialist
- Endocrinologist
- Diabetes Educator
- Dietitian
- Dentist
- Podiatrist
Is the person using diabetogenic medicines?
- Steroids
- Antipsychotics
OR using other medicines known to increase
blood glucose?
- Thiazide diuretics
- Sympathomimetics
- Pentamidine
- Dilantin/phenytoin
- Calcium channel blockers
- Enteral nutrition supplements e.g. Glucerna
• Undertake a comprehensive assessment
• Assess presence of diabetes risk factors
(refer to Part 1, Section B)
• Undertake a comprehensive medicine review
• Assess for occult infections
© Copyright 2010
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• Provide education about
steroids and diabetes
• Review need to continue
diabetogenic medicines
• Monitor according to steroid
medicine guidelines but
individualise according to
Advanced Care Directive
and PCOC* phase
• Commence OHA/insulin+
to control hyperglycaemic
symptoms and promote
comfort
• Assess enteral feeds –
may lack carbohydrate,
which can contribute to
lethargy OR may be high
calorie and contribute to
hyperglycaemia
• Consider adrenal
suppression and
hypercalcaemia as
complicating factors if
steroids are needed in the
long term
• Adjust OHA/insulin+ if
steroids are ceased and
when weaning the dose to
avoid hypoglycaemia
Guidelines for managing diabetes at the end of life Part 1, Section B
*Palliative Care Outcomes Collaboration (PCOC)
**Random venous blood glucose  11.1 mmol/L or fasting blood glucose  7.0 mmol/L
+Oral hypoglycaemic agents/insulin
Screening process for all people when they are first
refered to palliative care, regardless of PCOC* phase
DIABETES STATUS
UNKNOWN
Is the person using
diabetogenic medicines
AND has hyperglycaemia?**
• Undertake a comprehensive assessment
• Assess presence of diabetes risk factors
• Undertake a comprehensive medicine review
• Assess for occult infections
Are three or more diabetes
risk factors present:
- Family history
- Ethnicity (e.g.  Asian,
Pacific Islander,
Australian Aboriginal)
- Overweight, especially
central obesity
- Over age 50
- History of gestational
diabetes
- Schizophrenia
- Pancreatic cancer
AND/OR are hyperglycaemic
symptoms present?
• Commence diabetes
management and education
according to relevant diet
and activity guidelines
• Commence OHA/insulin+
if appropriate
• Consider referring to:
- Treating Specialist
- Endocrinologist
- Diabetes Educator
- Dietitian
- Dentist
- Podiatrist
Does the person have
hyperglycaemia?**
• Continue screening
• Monitor blood glucose levels
especially fasting and
towards the end of the day
• Monitor for hyperglycaemic
symptoms
© Copyright 2010
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Guidelines for managing diabetes at the end of life Part 2, Section A
Recommended diabetes management for
Type 1 and Type 2 Diabetes*
PCOC** PHASE:
STABLE
D
IA
B
ET
ES
 A
PP
R
OA
CH
A
SS
ES
SM
EN
T
M
A
N
AG
EM
EN
T
• Review/document diabetes management plan including
medicines: insulins, oral hypoglycaemic agents
(OHA)/Incretins
• Document presence of diabetes-related symptoms
(see Table 1 in accompanying document)
• Document diabetes short and long term complication status
• Ascertain self-care capacity and carer involvement
and capacity
• Consult with GP, diabetes educator, endocrinologist
• Check continuing and planned treatments
e.g. dialysis, chemotherapy, radiotherapy, surgery
• Revise or commence Advanced Care Directive that
includes diabetes management
• Provide information/discuss management with
patients and family members/carers
Long term
(1) Microvascular disease
- retinopathy
- nephropathy
(2) Macrovascular disease
- cardiovascular disease
- cerebrovascular disease
- intermittent claudication
(3) Neuropathy
- peripheral
- autonomic (responsible for gastroparesis and
hypoglycaemia unawareness)
• Review medicines using Quality Use of Medicines (QUM)
framework (see page 3 accompanying document)
• Ascertain whether patient is using complementary
medicines and/or other therapies
• Caution with renally excreted medicines and
eGFR < 60ml/min
• Assess presence of diabetes-related symptoms
• Assess diabetes complications:
Short term
- Hypoglycaemia
- Hyperglycaemia
- Active infection
TYPE 1
• Continue usual management
• Insulin regimen might need to be adjusted
TYPE 2
• Decide whether oral hypoglycaemic agents (OHAs)
are still appropriate
• Simplify medicines regimen if possible
• Consider using insulin – may be required if
altering/ceasing OHAs and/or to control symptoms
NOTE:
For all PCOC phases when patient is on OHAs and Incretins
- Risk of hypoglycaemia is increased with sulphonylureas
if renal or liver disease is present
- Metformin and alpha-glucosidase inhibitors can
exacerbate gastrointestinal (GI) symptoms, nausea,
vomiting, diarrhoea
- Metformin increases the risk of lactic acidosis and should
be stopped temporarily if radio-contrast media are used
in investigative procedures
- Incretin mimetics cause nausea, vomiting, weight loss
and reduce appetite
- Be aware of relevant contraindications e.g.
Thiazolidinediones (TZDs) e.g. oedema,  congestive cardiac
failure (CCF)
- Consider the side effects of medicines chosen e.g.
Metformin (GI symptoms), opioids (opioid-induced bowel
dysfunction, neurological changes, masks hypoglycaemia)
*Information relates to patients with Type 1 or Type 2 Diabetes unless otherwise stated
**Palliative Care Outcomes Collaboration (PCOC)
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Guidelines for managing diabetes at the end of life Part 2, Section B
Recommended diabetes management for
Type 1 and Type 2 Diabetes*
PCOC** PHASE:
UNSTABLE
*Information relates to patients with Type 1 or Type 2 Diabetes unless otherwise stated
**Palliative Care Outcomes Collaboration (PCOC)
D
IA
B
ET
ES
 A
PP
R
OA
CH
A
SS
ES
SM
EN
T
M
A
N
AG
EM
EN
T
• Review/document diabetes management plan including
medicines: insulins, OHAs/Incretins
• Document presence of diabetes-related symptoms
(see Table 1 in accompanying document)
• Document diabetes short and long term complication
status
• Ascertain self-care capacity and carer involvement
and capacity
• Consult with GP, diabetes educator, endocrinologist
• Check continuing and planned treatments
e.g. dialysis, chemotherapy, radiotherapy, surgery
• Revise or commence Advanced Care Directive that
includes diabetes management
• Provide information/discuss management with
patients and family members/carers
Assess symptoms:
- Pain
- Nausea/vomiting
- Oral intake/ pathology
- Delirium
Consider diabetes as a cause of the symptoms
Consider the impact of the symptoms on diabetes
(See Table 1 in accompanying document)
Decide whether symptoms represent a diabetes,
oncology or other emergency
Initiate management strategies:
• Monitor BG up to 4/day to determine whether
symptoms are diabetes-related and/or contribute
to the unstable state
• Blood glucose targets: Fasting 6-8 mmol/L,
Postprandial 6-11 mmol/L
• Initiate or change medicines if indicated:
- Increase or decrease dose
- Alter dose interval
• Ensure emergency medicines are available
• Provide diabetes management contingency plans
for patient and family/carer
TYPE 1: Monitor blood ketones
TYPE 2: Consider introducing insulin
If an emergency:
• Treat underlying
cause
• Decide whether
admission to
hospital (and/or
ICU depending
on prognosis) is
necessary
• Consider referring
to endocrinologist
• Provide education if
medicines change
• Manage comfort
and support family
• Monitor response
If not an emergency:
• Manage comfort
and support family
• Monitor diabetes
status
• Consider initiating
management
strategies (see left)
- Infection – occult or
overt sepsis
- Depression/anxiety
- Acute dyspnoea
- Polyuria, oliguria, thirst
- Anorexia
- Cachexia
- Decreasing performance status
© Copyright 2010
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Guidelines for managing diabetes at the end of life Part 2, Section C
Recommended diabetes management for
Type 1 and Type 2 Diabetes*
PCOC** PHASE:
DETERIORATING
D
IA
B
ET
ES
 A
PP
R
OA
CH
A
SS
ES
SM
EN
T
M
A
N
AG
EM
EN
T
• Review/document diabetes management plan including
medicines: insulins, OHAs/Incretins
• Document presence of diabetes-related symptoms
(see Table 1 in accompanying document)
• Document diabetes short and long term complication
status
• Ascertain self-care capacity and carer involvement
and capacity
• Consult with GP, diabetes educator, endocrinologist
• Check continuing and planned treatments
e.g. dialysis, chemotherapy, radiotherapy, surgery
• Revise or commence Advanced Care Directive that
includes diabetes management
• Provide information/discuss management with
patients and family members/carers
Consider in particular:
- Anorexia
- Cachexia
- Decreasing performance
status
Assess symptoms:
- Pain
- Nausea/vomiting
- Oral intake
- Oral pathology
- Delirium
- Infection – occult or overt
sepsis
- Depression/anxiety
- Acute dyspnoea
- Polyuria, oliguria, thirst
Consider diabetes as a cause of the symptoms
Consider the impact of the symptoms on diabetes
(See Table 1 in accompanying document)
Decide whether symptoms represent a diabetes,
oncology or other emergency
Re-evaluate diabetes management strategies
NOTE:
- BG and ketone monitoring is still useful to
determine whether ketosis exists but may be
less frequent (1-2 /day)
- New blood glucose targets < 10 mmol/L fasting
- Ensure medicines are optimal for this phase –
cease unless using to promote comfort
TYPE 2:
Consider introducing insulin to promote comfort
If an emergency:
• Treat the
underlying cause
• Decide whether
admission to
hospital is
necessary
• Consider referring
to endocrinologist
• Manage comfort
• Monitor response
If not an emergency:
• Manage comfort
• Consider initiating
management
strategies (see left)
• Implement
additional
support/education
for family/carers
*Information relates to patients with Type 1 or Type 2 Diabetes unless otherwise stated
**Palliative Care Outcomes Collaboration (PCOC)
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Guidelines for managing diabetes at the end of life Part 2, Section D
Recommended diabetes management for
Type 1 and Type 2 Diabetes*
PCOC** PHASE:
TERMINAL
D
IA
B
ET
ES
 A
PP
R
OA
CH
A
SS
ES
SM
EN
T
M
A
N
AG
EM
EN
T
• Review/document diabetes management including
medicines: insulins, OHAs/Incretins with a view to
ceasing
• Note: Carer involvement may increase
• Communicate with GP, palliative care specialist team
• Implement Advanced Care Directive
• Consider implementing the Liverpool Care Pathway
• Provide information/discuss management with patients
and family members/carers
• Assess whether short term diabetes complications need
to be treated to achieve comfort
• Refer to Advanced Care Directive
• Identify carer/family bereavement risks
• Assess and manage to alleviate symptoms
- Pain
- Nausea/vomiting
- Oral comfort
- Delirium
- Infection – occult or overt
- Depression/anxiety
- Acute dyspnoea
Focus of diabetes management is on comfort
Re-evaluate diabetes management strategies:
• Consider patient and carer preferences for diabetes
management
• Consider ceasing BG monitoring – check Advanced
Care Directive and/or discuss with carer if patient has
not given instructions to ensure monitoring is consistent
with the patient’s wishes
• Decide whether care is provided in home/hospital care
Note: Medicines may not be appropriate except to achieve
comfort. Rationalise medicines and stop any that are
unnecessary
*Information relates to patients with Type 1 or Type 2 Diabetes unless otherwise stated
**Palliative Care Outcomes Collaboration (PCOC)
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Guidelines for managing diabetes at the end of life Part 3, Section A
Managing steroids and other diabetogenic
medicines in palliative care patients
TYPE 1 DIABETES
D
IA
B
ET
ES
 A
PP
R
OA
CH
A
SS
ES
SM
EN
T
M
A
N
AG
EM
EN
T
• Short course not causing symptoms or ketosis may not
require regimen changes but effects on blood glucose
often occur after 1-2 doses
• Courses > three days usually require regimen changes
 NOTE:
Long term steroid use can:
- cause hypercalcaemia
- suppress the hypothalamic-pituitary-adrenal axis
Both states can complicate management but may not
be relevant depending on the prognosis
• Commence BG monitoring – consider increasing
frequency while on diabetogenic medicines
(e.g. 3-4/day)
• Revise diet and exercise routines but note food choices
should not be limited if the person is cachectic or
anorexic
• Revise medicine regimen: if possible avoid other
diabetogenic medicines or use lowest possible dose
• Conduct a collaborative team meeting with specialists
– Palliative, diabetes educator, endocrinologist, and
patient and family/carers
• Ascertain patient/carer education requirements –
Appropriate medicine self-management (when, how,
why, interactions, side effects)
- BG testing
- Increased risk of hypoglycaemia if hypo
unawareness is present especially when weaning
or ceasing steroids
• Increase insulin dose if BG > 10 mmol/L especially if
ketones are present.
• Note: Patients in ICU or fasting may require an insulin
infusion
• Use subcut insulin if eating
• Adjust prandial doses because the post prandial BG
tends to increase.
• Consider the effect of the carbohydrate meal content
on BG and the need to provide energy if patient is on
enteral feeds
• Monitor and record BG before meals and before bed
• Monitor blood ketones if BG >15 mmol/L
• Manage hyperglycaemia and hypoglycaemia
• An AM insulin dose may be needed because BG often
peaks early PM and tends to fall overnight
• Revise patient and carer knowledge and provide
education especially managing hyperglycaemia if
managed at home
• Consider need for access to ‘on call/after hours’ support
© Copyright 2010
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Guidelines for managing diabetes at the end of life Part 3, Section B
Managing steroids and other diabetogenic
medicines in palliative care patients
TYPE 2 DIABETES
or previously undiagnosed diabetes
D
IA
B
ET
ES
 A
PP
R
OA
CH
A
SS
ES
SM
EN
T
M
A
N
AG
EM
EN
T
• Short course not causing symptoms or hyperosmolar
non-ketotic acidosis (HONK) may not require regimen
changes but effects on BG often occur after 1-2 doses
• People with Type 2 can develop ketoacidosis during
significant illnesses
• Courses > three days usually require regimen changes
 NOTE:
Long term steroid use can suppress the
hypothalamic-pituitary-adrenal axis.
This can complicate management but may not be
relevant depending on the prognosis
• Ascertain patient/carer education requirements –
Appropriate medicine self-management (when, how,
why, interactions, side effects); hypoglycaemia
management
- BG testing
• Revise diet and exercise routines but note food choices
should not be limited if the person is cachectic or
anorexic
• Commence BG monitoring – consider increasing
frequency while on diabetogenic medicines
(e.g. 3-4/day or fasting and pre-evening meal)
• Revise medicine regimen: if possible avoid other
diabetogenic medicines or use lowest possible dose
for the shortest possible time
• Conduct a collaborative team meeting with
specialists – Palliative, diabetes educator,
endocrinologist and oncologist, and patient and
family/carers
• Oral hypoglycaemic agents may need to be altered
• Consider commencing insulin if BG is consistently
> 11 mmol/L
• Consider insulin preparations
- Prebreakfast long acting analogue such as lantus
or protaphane OR
- Premixed insulin before lunch e.g. mixtard  30/70
• Note: Patients in ICU or fasting may require an insulin
infusion
• Consider the effect of the carbohydrate meal content
on BG and the need to provide energy if patient on
enteral feeds
• Monitor and record BG before meals and before bed
• Manage hyperglycaemia and hypoglycaemia
• Revise patient and carer knowledge especially
managing hyperglycaemia if managed at home
• Consider need for access to ‘on call/after hours’ support
© Copyright 2010
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BRIEF INFORMATION TO ACCOMPANY THE
Guidelines for managing diabetes at the end of life
OUTLINE OF DIABETES MANAGEMENT
In general diabetes management involves an appropriate diet and activity for both type 1 and type 2 diabetes even when
medicines are needed. Managing diabetes involves:
• Lifestyle changes particularly for type 2 diabetes
• Medicines:
- Type 1 diabetes – insulin
- Type 2 diabetes oral hypoglycaemic agents and/or insulin
Note: beta cell function declines over time and approximately 75% of people with type 2 diabetes need insulin
• Managing blood glucose, lipids and blood pressure
• Regular medicines review
• Regular monitoring by health professionals to identify and manage the short and long term complications of diabetes
• Diabetes education including educating significant others
• Self-care by the patient, support from family/carer
HYPERGLYCAEMIA AND HYPOGLYCAEMIA
Two conditions commonly associated with diabetes are hyperglycaemia, a symptom of diabetes, and hypoglycaemia, a
side effect of oral hypoglycaemic agents, especially sulphonylureas and insulin.
Hyperglycaemia
Under usual circumstances, many people with type 2 diabetes do not experience the symptoms of hyperglycaemia until
their blood glucose levels are extremely high.  Common symptoms of hyperglycaemia include:
• Feeling excessively thirsty • Frequently passing large volumes of urine
• Feeling tired • Blurred vision
• Infections e.g. thrush, cystitis, wound infections • Lowered mood
• Weight loss in the longer term (Diabetes Australia, 2009)
Hypoglycaemia
Hypoglycaemia, also called a ‘hypo’, low blood glucose or insulin reaction, occurs when the blood glucose level falls
below 3.5 mmol/L in people on OHA or insulin. Symptoms of hypoglycaemia vary from person-to-person, however,
common feelings are:
• Weakness, trembling or shaking • Sweating
• Light headedness • Headache
• Dizziness • Difficulty concentrating
• Tearful/crying • Behaviour change
• Irritability • Hunger
• Numbness around the lips and fingers (Diabetes Australia, 2009)
Hypoglycaemia unawareness may be present, especially in people with long-standing type 1 diabetes. This means they
may not recognise the symptoms of hypoglcycaemia. In addition, symptoms may be masked by analgesia, delirium and
other cognitive changes and cancer-related autonomic neuropathy. Significantly, both people with diabetes and their family
members/carers are often very fearful of hypos and their consequences.
© Copyright 2010
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CORTICOSTEROID MEDICINES
Corticosteroid medicines, more specifically the glucocorticoids (often referred to as steroids), are an essential part of the
management of several disease processes such as haematological malignancies, inflammatory diseases, allergies and
shock.  However, long term use and high doses predisposes people to insulin resistance (IRS), glucose intolerance (IGT)
and steroid-induced diabetes and causes hyperglycaemia and the resultant symptoms in people with diagnosed diabetes.
 IRS and IGT can occur within 48 hours of commencing steroids, especially in at risk individuals and those with diabetes.
People should be informed they could develop diabetes when diabetogenic medicines are prescribed.
THE QUALITY USE OF MEDICINES FRAMEWORK
The Quality Use of Medicines (QUM) Framework (PHARM Committee, 2005) is the recommended Australian framework for
making medicines-related decisions and was used to formulate these guidelines (see Figure 1, next page).
Factors to consider when determining diabetes medicine regimen for people with diabetes
receiving palliative care – if medicines are indicated
• Insulin doses may need to be adjusted frequently.
• Patients on metformin who develop nausea and vomiting especially the elderly, those on diabetogenic medicines, and
those with reduced renal function, liver, cardiac and respiratory disease, and people who are not eating may be at risk
of lactic acidosis, a rare but serious adverse event. Therefore, metformin may not be the best choice.
• Insulin mimetics can induce weight loss and nausea and may be contraindicated.
• Thiazolidinediones (TZDs) contribute to weight gain due to fluid retention and may be contraindicated.
• Diuretics can exacerbate dehydration and increase blood glucose levels.
• Corticosteroids, and atypical antipsychotics are frequently used in palliative care and other disease processes and
increase blood glucose levels.
• Glucagon used to treat severe hypoglycaemia usually increases blood glucose quickly. A second dose can induce
nausea but may be ineffective in emaciated people with reduced glycogen stores. This means if oral glucose treatment
of hypoglycaemia and IM glucagon are ineffective or contraindicated, IV dextrose may be required.
• Some oral nutrition supplements affect blood glucose levels, often leading to hyperglycaemia.
• The patient may be using complementary medicines (CAM) and other CAM therapies. If so, determine why the person
is using CAM, what they are using, and whether CAM is appropriate i.e. the benefits outweigh the risks and there is
evidence for its use.
• CAM medicines may interact with conventional medicines. However, some non-medicine CAM therapies can relieve
symptoms and may be safer than medicines.
• Opioids and other psychoactive medicines can mask hypoglycaemia.
Brief information to accompany the Guidelines for managing diabetes at the end of life
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Refer all patients
with diabetes to:
• Diabetes
specialist
• Diabetes
educator
• Dietitian
• Other health
professionals
as indicated
YES NO
Brief information to accompany the Guidelines for managing diabetes at the end of life
EARLY IDENTIFICATION
OF DIABETES
If the patient is on corticosteroids or diabetogenic medicines:
• Conduct diabetes risk assessment
• Review medicines, including complementary medicines
• Provide appropriate medicine and/or lifestyle advice
• Monitor—blood glucose, ketones
• Check for signs and symptoms of diabetes, increased blood glucose
• Oral health check
FIGURE 1: Quality Use of Medicines Framework for managing diabetes at the end of life
See Diabetes
Screening Process
(Part 1, Section B)
AND Managing
Steroids
Guidelines (Part 3,
Secion A/B)
• Determine whether medicines are needed to manage diabetes
• Conduct a medicines review encompassing:
- Type 1 – Insulin
- Type 2 – OHA or insulin, depending on the physical assessment: renal, liver,
respiratory, and gastrointestinal factors that could affect medicine
pharmacokinetics and pharmacodynamics.
- For patients on diabetogenic medicines, consider whether they can be stopped
or doses or dose intervals adjusted or an alternative formulation can be used?
• Consider the need for other medicines to manage other conditions including the
indication for palliative care, which could be diabetes-related e.g. end-stage renal
disease.
Is the patient taking any medicines to manage diabetes?
Diabetes present
as existing
diagnosis or
develops during
palliative care
process
• Consider self-care potential
• Determine whether oral route
possible or another route is
indicated, e.g. insulin infusion?
• Consider  the complexity of
regimen. Is insulin simplest
choice?
• Provide education including ‘sick
day care’
• Develop medicine management
plan, a plan for monitoring
outcomes and for stopping
medicines when indicated,
develop Advanced Care Directives
(ACD)
• Decide alternative management
strategies relevant to PCOC phase
• Medicines may need to be ceased
for patients in the terminal phase
but may be needed to maintain
comfort and control symptoms
• Consider Advanced Care
Directives (ACD)
© Copyright 2010
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PALLIATIVE CARE SYMPTOMS AND DIABETES
Sub-optimal symptom control can be due to the diabetes or the life threatening primary illness or both. Distinguishing
cause and effect can be difficult. Symptoms not caused by diabetes can have significant effects on diabetes management.
Table 1 (next pages) presents the relationships between common palliative care symptoms and diabetes.
Table 1: The relationship between common palliative care symptoms and diabetes
Pain (acute/chronic) Increased:
- somnolence or confusion/cognitive impairment due
to pain/analgesia
- risk of hyperventilation
- hyperglycaemia
Reduced:
- intake
- mobility
- sleep
- self-care ability
- quality of life
- Peripheral vascular disease
- Amyotrophy
- Peripheral neuropathy
- MI
- Tissue glycosylation
(e.g. carpel tunnel syndrome)
- Ketoacidosis (abdominal pain)
Depression/anxiety Increased:
- fatigue
- lethargy, change in performance status
- risk of DKA, HONK
- social isolation
Reduced:
- self-care ability, disinterest increased risk of
hyperglycaemia
- confidence
- inadequate nutrition increased risk of hypoglycaemia
- effects on communication and self-care
- Associated with diabetes especially
hyperglycaemia
- Renal disease
- Steroid medicines
- Hypoglycaemia symptoms can be
mistaken for anxiety
Increased:
- pain
- dry mouth
- inadequate nutrition, inappropriate weight loss,
cachexia
- hypoglycaemia if on OHA/insulin
Reduced:
- intake
- self-care deficits
- mood
Oral Pathology (oral and
maxillofacial pathology  –
WHO): Mucositis, ulcers,
dry mouth
- DKA, HONK may lead to dry mouth,
thirst and clinical dehydration
- Risk of dental caries and oral
pathology
- Risk of hypoglycaemia if on OHAs
or insulin
Nausea/vomiting Increased:
- confusion
- lethargy
- disinterest
- pain/discomfort
- inadequate nutrition – weight loss, cachexia,
hyperglycaemia
- hypoglycaemia if on OHA/insulin
- dehydration and electrolyte imbalance
- risk of ketoacidosis
Reduced:
- intake
- energy, depleted energy stores
- May be due to gastric autonomic
neuropathy
- Renal disease
- Hyperglycaemia – DKA, HONK
Medicines:
Metformin
Byetta
COMMON PALLIATIVE
CARE SYMPTOMS IMPACT ON DIABETES MANAGEMENT MAY BE DIABETES-RELATED
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Delirium Increased:
- cognitive impairment
Reduced:
- ability to communicate and detect signs/symptoms of
hypo/hyperglycaemia
- self-care ability
- May be due to many factors
including hyper and hypoglycaemia
Sepsis Increased:
- confusion
- energy requirements
- pain
- difficulty interpreting elevated white cell count, which
could be caused by  hyperglycaemia, sepsis, or other
factors
- bone marrow failure
Reduced:
- intake increased DKA, HONK risk
- quality of life
- wound healing
- May be silent in diabetes (UTI, MI)
- May precipitate DKA, HONK
Increased:
- hypoxia contributing to confusion
Reduced:
- self-management capacity
Note: MI often silent in diabetes
Acute Dyspnoea - Tachypnoea may be due to DKA and
resultant metabolic acidosis
- Kussmaul breathing in early stages
of DKA could be mistaken for
Cheyne-Stokes respiration
- Consider lactic acidosis if taking
Metformin
Diabetes Emergencies Examples:
- Hypoglycaemia
- Hyperglycaemia
- MI
- Hypoglycaemia
- DKA, HONK, Lactic acidosis
Table 1 (continued): The relationship between common palliative care symptoms and diabetes
Examples:
- Spinal Cord Compression (glucocorticoids) and acute
immobility
- SVC obstruction (acute dyspnoea and delirium) - high
dose of glucocorticoids
- Febrile neutropenia
- Major bronchial obstruction (dyspnoea and use of
glucocorticoids)
Oncology Emergencies - Hypoglycaemia
- DKA, HONK, Lactic acidosis
COMMON PALLIATIVE
CARE SYMPTOMS IMPACT ON DIABETES MANAGEMENT MAY BE DIABETES-RELATED
© Copyright 2010
14
Palliative Care Resources
Clayton J, Hancock K, Butow P, Tattesall M, Currow D.
(2007). Clinical practice guidelines for communicating
prognosis and end of life issues with adults in the
advanced stages of a life threatening illness, and their
caregivers. Medical Journal of Australia 186 (12):
S76–S108.
Ellershaw J, Smith C, Overill S, Walker S, Aldridge J. (2001).
Care of the dying: setting standards for the symptom
control in the last 48 hours of life. Journal of Pain and
Symptom Management  21 (1): 12–17.
Fallon M, Hanks G. (eds) (2006). ABC of Palliative Care.
Blackwell Publishing Ltd. Oxford.
Fitzsimons D, Mullan D, Wilson J, et al. (2007) The Challenge
of patients’ unmet palliative care needs in the final stages
of chronic illness. Palliative Medicine 21 (4): 313–322.
Glare P, Auret K, Aggarwal G, Clark K, Pickstock S,
Lickiss N. (2003). The interface between palliative
medicine and specialists in acute-care hospitals:
boundaries, bridges and challenges Medical Journal of
Australia 179 (6): S29–S31.
CareSearch. (2010). Palliative care knowledge network.
http://www.caresearch.com.au/Caresearch/Default.aspx
Therapeutic Guidelines. (2010). Palliative Care Version 3.
Therapeutic Guidelines Limited, North Melbourne
Diabetes Management Resources
Dunning T. (2009). Care of People with Diabetes: a Manual
of Nursing Practice. 3rd edition, Wiley-Blackwell,
Chichester UK.
Therapeutic Guidelines (2009). Endocrinology version 4,
2009. Victoria.
http://www.tg.org.au/index.php?sectionid=44#mozTocI
d587241
End of Life Resources
Kuhl D. (2005). What Dying People Want: Practical Wisdom
for the End of Life. Australian Broadcasting Corporation,
Sydney, NSW.
SUGGESTED READING
15
